کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3879766 1599025 2006 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Circulating Chromogranin A and Hormone Refractory Prostate Cancer Chemotherapy
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی بیماری‌های کلیوی
پیش نمایش صفحه اول مقاله
Circulating Chromogranin A and Hormone Refractory Prostate Cancer Chemotherapy
چکیده انگلیسی

PurposeNeuroendocrine differentiation is a frequent pattern in prostate adenocarcinoma. CgA seems to be a useful indicator of neuroendocrine differentiation in patients with HRPC. We evaluated the clinical interest of circulating CgA in HRPC.Materials and MethodsSerum CgA was assessed by immunoradiometric assay in 39 patients with HRPC treated with paclitaxel and carboplatin or mitoxantrone. Baseline CgA and its variation during chemotherapy were studied.ResultsIncreased serum CgA was observed in 45% of patients. Previous local radiotherapy and the duration of hormonal therapy were independent factors that influenced CgA. There was no correlation between CgA and prostate specific antigen. Increased serum CgA showed positive predictive significance but no prognostic value. The chemotherapy response correlated with a CgA decrease of greater than 25%.ConclusionsThe current study suggests that CgA assessment facilitates patient selection by predicting the chemotherapy response and providing complementary information to follow the chemotherapy response.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The Journal of Urology - Volume 175, Issue 4, April 2006, Pages 1347–1352
نویسندگان
, , , , , ,